Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Treats fibromyalgia.

UsesSide effectsLatest evidence reviewsResearch summaries for consumersBrand names

Results: 1 to 20 of 22

Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis

OBJECTIVES: To evaluate and compare the efficacy and acceptability of the antidepressants amitriptyline (AMT), duloxetine (DLX) and milnacipran (MLN) for FM syndrome (FMS).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

The authors concluded that there was evidence of the short-term (up to six months) efficacy of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome; the drugs differed in their effects on fibromyalgia syndrome domains and side-effects. The conclusions about the relative efficacy of drugs were not based on direct comparisons and may not be definitive.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Milnacipran for chronic neuropathic pain and fibromyalgia in adults

The aim of this review was to assess how effective milnacipran is for treating chronic neuropathic pain or fibromyalgia. We identified no studies using milnacipran in neuropathic pain, but five studies in fibromyalgia satisfied the inclusion criteria. Fibromyalgia is a complex pain syndrome, defined as widespread pain for longer than three months; the original diagnostic criteria involved pain on palpation at 11 or more of a number of specified tender points (Wolfe 1990), with later criteria including both widespread pain and symptom severity (Wolfe 2010). The studies included over 4000 participants treated with milnacipran 100 mg or 200 mg, or placebo, for eight to 24 weeks at the target dose. Overall study quality was good, although the method of analysis for our primary outcomes could overestimate treatment effect.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

Milnacipran versus other antidepressive agents for depression

Major depression, also known as major depressive disorder or unipolar depression, is a common mental disorder characterised by a combination of symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy pleasurable activities. An episode of major depression may occur only once in a person's lifetime, but more often, it recurs throughout a person's life.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Comparing Fibromyalgia Drugs

How do drugs for fibromyalgia compare in improving symptoms?

PubMed Clinical Q&A [Internet] - National Center for Biotechnology Information (US).

Version: June 12, 2011

Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet]

We compared the effectiveness and harms of tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, noradrenergic and specific serotonergic reuptake inhibitor, norepinephrine and dopamine reuptake inhibitor, serotonin receptor antagonist, antiepileptic drugs, and skeletal muscle relaxants in adults with fibromyalgia.

Drug Class Reviews - Oregon Health & Science University.

Version: April 2011
Show search results within this document

Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care

This guideline has been developed to advise on supporting people with dementia and their carers in health and social care. The guideline recommendations have been developed by a multidisciplinary team of health and social care professionals, a person with dementia, carers and guideline methodologists after careful consideration of the best available evidence. It is intended that the guideline will be useful to practitioners and service commissioners in providing and planning high-quality care for those with dementia while also emphasising the importance of the experience of care for people with dementia and carers.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2007
Show search results within this document

Serotonin and noradrenaline reuptake inhibitors for fibromyalgia

Researchers in the Cochrane Collaboration conducted a review of research about the effects of serotonin and noradrenaline reuptake inhibitors (SNRIs) on fibromyalgia syndrome (FMS). After searching for all relevant studies, they found 10 studies with up to 6038 people. Their findings are summarized below.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

A meta-analysis of pain response in the treatment of fibromyalgia

This review concluded that eight active treatments showed evidence of an improvement in pain over placebo in patients with fibromyalgia. Indirect comparison of active treatments found no strong differences. These conclusions should be interpreted with caution in view of the risk of publication bias and the small number of included studies for each comparison.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Novel antidepressants and panic disorder: evidence beyond current guidelines

AIM: The aim of the present review is to summarize available evidence about the efficacy and side effects of novel antidepressants for the treatment of panic disorder.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia

OBJECTIVES: To review the literature on pharmacological treatments for fibromyalgia.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome

This review concluded that amitriptyline was effective in reducing the symptoms of patients with fibromyalgia syndrome, and some other antidepressants may also be useful. Despite the methodological strengths of the review processes, the inappropriate statistical analyses mean that these findings cannot be considered reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis

OBJECTIVES: The superiority of true drug treatment over placebo in reducing symptoms of fibromyalgia syndrome (FMS) is small and bought by relevant rates of drop-outs due to adverse events. Recent systematic reviews demonstrated that a substantial proportion of the beneficial and adverse effects of true drug is attributable to placebo in chronic pain trials. We determined the magnitude of the placebo and nocebo response and its impact on the benefits and harms of true drug in trials of drugs which were submitted for approval for treatment of FMS.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials

The review found that antidepressant treatment for major depression was effective, but that such treatment may have been less effective in later life than in a general adult population. Limitations in the conduct and reporting of the review, particularly lack of quality assessment, mean that the reliability and generalisability of the conclusions are uncertain.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis

BACKGROUND: The role of antidepressants in the management of fibromyalgia syndrome (FMS) still needs to be determined.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Fluoxetine compared with other antidepressants for depression in adults

Depression is a severe mental illness characterised by a persistent low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms such as appetite change, sleep disturbance and poor concentration. The predominant treatment options for depression are drugs and psychological therapies, but antidepressant drugs are the most common treatment for moderate to severe depression. Fluoxetine, one of the first new generation antidepressants, is an extremely popular drug treatment for depression. However, findings from studies comparing fluoxetine with other antidepressants are controversial. In this systematic review, the efficacy and tolerability of fluoxetine was compared with other antidepressants for the acute treatment of depression.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Evidence and Guidelines [Internet]

Gabapentin is an anticonvulsant drug that has been used for a number of off-label indications, including neuropathic pain. It is thought to act by binding to calcium channels and modulating calcium influx, or by blocking new synapse formation. Neuropathic pain tends to be chronic, is complex, and can be difficult to treat effectively. Treatment often involves pharmacologic and physical therapies, although conventional analgesics may not be effective.

Rapid Response Report: Summary with Critical Appraisal - Canadian Agency for Drugs and Technologies in Health.

Version: September 26, 2014
Show search results within this document

Depression: The Treatment and Management of Depression in Adults (Updated Edition)

This clinical guideline on depression is an updated edition of the previous guidance (published in 2004). It was commissioned by NICE and developed by the National Collaborating Centre for Mental Health, and sets out clear, evidence- and consensus-based recommendations for healthcare staff on how to treat and manage depression in adults.

NICE Clinical Guidelines - National Collaborating Centre for Mental Health (UK).

Version: 2010
Show search results within this document

Drug Class Review: Neuropathic Pain: Final Update 1 Report [Internet]

We compared the effectiveness and harms of anticonvulsants, tricyclic antidepressants, serotonin–norepinephrine reuptake inhibitors (SNRIs), and the lidocaine patchin adults with neuropathic pain.

Drug Class Reviews - Oregon Health & Science University.

Version: June 2011
Show search results within this document

Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review [Internet]

Depressive disorders such as major depressive disorder (MDD), dysthymia, and subsyndromal depression may be serious disabling illnesses. MDD affects more than 16 percent of adults at some point during their lifetimes. Second-generation antidepressants dominate the medical management of depressive disorders. These drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other drugs with related mechanisms of action that selectively target neurotransmitters.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: December 2011
Show search results within this document

Systematic Reviews in PubMed

See all (37)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...